Patent intelligence · US
US 10894044
Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer
Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer
Patent details — US 10894044
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 19, 2021
- Expiration
- Jan 14, 2041
- Claims
- 12
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K2039/545
Quick answer
US 10894044 (Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer) is held by The Board of Regents of the University of Texas System. Status: granted. Granted Jan 19, 2021. Expires Jan 14, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K2039/545, A61K2300/00, A61K31/4745
More from The Board of Regents of the University of Texas System
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 10894044?
US 10894044 (Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer) is held by The Board of Regents of the University of Texas System. Status: granted. Granted Jan 19, 2021. Expires Jan 14, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10894044?
The Board of Regents of the University of Texas System is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 10894044 expire?
Our index shows an expiration date of Jan 14, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.